期刊文献+

4-甲氧基-3-[3-(吗啉-4-基)丙氧基]苯甲腈的合成研究 被引量:1

Synthesis of 4-Methoxy-3-(3-morpholinopropoxy)benzonitrile
原文传递
导出
摘要 以3-羟基-4-甲氧基苯甲醛为原料,在甲酸、甲酸钠、盐酸羟胺作用下,将醛基转化为氰基,在含有碳酸钾的DMF中,所得化合物与N-(3-氯丙基)吗啉反应得目标化合物,总收率为87.5%。产物结构由1HNMR表征。本方法具有操作简单、易于纯化、收率高等特点,为工业化生产提供实验基础。 The titled compound was synthesized from 3-hydroxy-4-methoxybenzaldehyde.The formyl group was transformed to cyano group via the reaction with hydroxylammonium sulfate in the presence of sodium formate in formic acid,then the corresponding intermediate reacted with N-(3-chloropropyl)morpholine,the total yield was up to 87.5%.The products were characterized with 1H NMR.The synthetic route exhibits the advantages in purification and total yield of the final product compared with the previous ones.
出处 《化学通报》 CAS CSCD 北大核心 2012年第10期945-947,共3页 Chemistry
关键词 4-甲氧基-3-(3-吗啉-4-基丙氧基)苯甲腈 合成 工业化 4-Methoxy-3-(3-morpholinopropoxy)benzonitrile Synthetic Industrialization
  • 相关文献

参考文献3

二级参考文献29

  • 1[1]Natale R,Zaretsky SL.ZD1839 (IressaTM):what's in it for the patient[J].The Oncologist,2002,7(Suppl 4):S25-S30.
  • 2[2]Herbst RS,Kies MS.ZD1839 (IressaTM) in non-small-cell lung cancer[J].The Oncologist,2002,7(Suppl 4):S9-S15.
  • 3[3]Barker AJ,Gibson KH,Grundy W,et al.Studies leading to the identification of ZD1839(IRESSA):an orally active,selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer[J].Bioorg Med Chem,2001,11(14):1911-1914.
  • 4[4]Iwasawa A,Kumamoto Y,Fujinaga K.Detection of human papillomavirus deoxyribonucleic acid in penile carcinoma by polymerase chain reaction and in situ hybridization[J].J Urol,1993,149(1):59-63.
  • 5[5]Varma VA,Sancher LMM,Unger ER,et al.Association of human papillomavirus with penile carcinoma:a study using polymerase chain reaction and in situ hybridization[J].Hum Pathol,1991,22(9):908-913.
  • 6[6]Gorgoulis V,Aninos D,Mikou P,et al.Quantitative assay of epidermal growth rceptor in squamous cell lung carcinomas[J].Anti Cancer Res,1992,12(4):1183.
  • 7[7]Swaisland H,Laight A,Stafford L,et al.Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers[J].Clin Pharmacokinet,2001,40(4):297-306.
  • 8[8]Alderley P.ZD1839 ('Iressa'),an oral EGFR-TKI:pharmacokinetic results of a phase Ⅰstudy in patients with advanced cancer[A].AACR[C].San Francisco,CA,April 1-5,2000.
  • 9[9]Fukuoka M,Yano S,Giaccone G,et al.Final results from a Phase Ⅱ trial of ZD1839 ('Iressa') for patients with advanced non-small-cell lung cancer (IDEAL 1)[J].Proc Am Soc Clin Oncol,2002,21:298a(A1188).
  • 10[10]Kris MG,Natale RB,Herbst RS,et al.A phase Ⅱ trial of ZD1839 ('Iressa') in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum-and docetaxel-based regimens (IDEAL 2)[J].Proc Am Soc Clin Oncol,2002,21:292a(A1166).

共引文献28

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部